Kolexia
De La Motte Rouge Thibault Oncologie médicale
De La Motte Rouge Thibault
Oncologie médicale
Centre Eugène Marquis
Rennes, France
390 Activités
1.1 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs du sein Carcinome épithélial de l'ovaire Récidive tumorale locale Carcinomes Tumeurs du col de l'utérus Tumeurs de la prostate Tumeurs du péritoine Tumeurs du sein triple-négatives

Collaborateurs

Voir plus
Frenel Jean-Sebastien
Frenel Jean-Sebastien
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France
Pautier Patricia
Pautier Patricia
Gustave-Roussy, Villejuif, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
GSK
33 collaboration(s)
Dernière en 2023
Pfizer
25 collaboration(s)
Dernière en 2023
MSD
23 collaboration(s)
Dernière en 2023
Edimark
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
CUPCAKE: Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Essai Clinique (Institut Curie)   06 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
Actualités au congrès en oncosénologie de San Antonio 2023
Edimark   31 janvier 2024
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Molecular oncology   29 janvier 2024
Cancers gynécologiques
Edimark   21 décembre 2023
GREAT: Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
Essai Clinique (AstraZeneca)   13 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
GYNET: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Essai Clinique (NETRIS Pharma)   24 novembre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023